Nek­tar crushed — again — as Bris­tol My­ers al­ly runs in­to PhI­II melanoma fail

Nek­tar could not hold up to Bris­tol My­ers’ block­buster Op­di­vo in a Phase III melanoma study, as the com­bo ther­a­py went 0-for-3 on ma­jor mark­ers, lead­ing the CEO to sug­gest lay­offs could be on the way.

The pair had been aim­ing to com­bine Op­di­vo with Nek­tar’s ex­per­i­men­tal drug ​​be­m­pe­galdesleukin, or be­m­peg for short, in metasta­t­ic melanoma. It’s an in­di­ca­tion that made the PD-(L)1 class fa­mous, as it was where Op­di­vo and ri­val Keytru­da were first eval­u­at­ed and nabbed their ini­tial ap­provals be­fore each be­com­ing megablock­busters.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.